Roth Affirms Keryx (KERX) at 'Buy'; ESRD Overhang Removed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
H.C. Wainwright Reiterates Buy on Keryx Biopharmaceuticals (KERX)
April 2, 2014 1:15 PM EDTH.C. Wainwright reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a price target of $21.00. Comments follow news the EMA plans to review Zerenex's MAA.
Analyst Reni Benjamin said, "Today, Keryx announced the European Medicines Agency (EMA) initiated a formal review of... More
Keryx Biopharma (KERX) Reports EMA Validation of Zerenex MAA
April 2, 2014 8:31 AM EDTKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that the European Medicines Agency ("EMA") has determined that the Company's Marketing Authorization Application ("MAA") seeking the approval of Zerenex (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis-dependent CKD, is valid. Validation of the MAA confirms that the submission is sufficiently... More
